Following two rounds of pipeline prioritizations in a year, Repare reaffirmed this morning that it is focused on a pair of ...

H.C. Wainwright lowered the firm’s price target on Repare Therapeutics (RPTX) to $5 from $10 and keeps a Buy rating on the shares following the Q4 report. The firm removed revenue projections ...

Repare Therapeutics saw its stock climb in after-hours trading Tuesday after disclosing a global licensing deal with Switzerland-based Debiopharm International for lunresertib, a first-in-class PKMYT1 ...

Stifel lowered the firm’s price target on Repare Therapeutics (RPTX) to $3 from $4 after the company announced a re-alignment of resources and a re-prioritization of its clinical portfolio to ...

Repare Therapeutics on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11. He succeeds Lloyd Segal, who ...

Repare Therapeutics Announces Leadership Transitions. Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte, E ...